As the tech world's giants build their AI ambitions, chip designer Arm Holdings stands at the center. With its Q3 earnings report on the horizon, investors are weighing whether its foundational role justifies a premium valuation.
Wall Street firms have issued a series of bullish upgrades for Karman Holdings Inc. (KRMN), significantly raising revenue projections and price targets for the specialty materials company as growth expectations accelerate.
Karman Holdings (NYSE: KRMN) is capturing Wall Street's attention as a series of bullish analyst calls, including a significant price target hike from KeyBanc, fuel its ascent. The stock's rally is tied to sustained momentum in the aerospace and defense sector, though some advise caution after its rapid gains.
Analysts at Susquehanna upgrade Arm Holdings to Positive, citing transformative deals with OpenAI and Meta. The firm projects a new AI XPU could generate over $1 billion in annual royalties, signaling a major shift beyond Arm's mobile roots.
A sharp 16% weekly decline in enGene Holdings' share price puts significant pressure on its largest shareholder group—private equity firms controlling nearly half the company—raising questions about strategy and future direction amid broader market volatility.
Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.
Insiders at Chasen Holdings have been net buyers over the past year, with a key director significantly increasing his holdings. High insider ownership aligns leadership with shareholder interests, signaling internal optimism amid market fluctuations.
A deep dive into Wing Tai Holdings' share registry reveals a concentrated ownership structure, with private companies controlling 51% of the Singapore-listed property group. Individual investors, however, represent a significant 33% bloc, raising questions about governance dynamics and future strategic direction.
An analysis of Mooreast Holdings' financial metrics reveals a worrying trend of declining returns on capital employed, despite growth in its asset base. The company's performance lags behind its own historical figures, prompting a closer look from the market.
Hilltop Holdings capped off 2025 with a 46% surge in net income, fueled by a steeper yield curve and disciplined cost management across its banking and securities units. While the mortgage division remains under pressure, executives point to a robust loan pipeline and shareholder returns as signs of resilience heading into 2026.
While high-risk tech stocks dominate headlines, Skellerup Holdings (NZSE:SKL) demonstrates how consistent EPS growth, disciplined leadership compensation, and strong insider alignment can build a resilient investment case in uncertain times.
Despite a challenging mortgage landscape and specific credit headwinds, Hilltop Holdings Inc. (HTH) reported a 46% surge in annual net income for 2025, buoyed by a steepening yield curve and disciplined cost management across its banking, lending, and securities divisions.
Amidst a market often captivated by speculative stories, Thermon Group Holdings (NYSE: THR) presents a profile built on profitability, steady growth, and aligned leadership—factors that seasoned investors typically watch for.
Defying a challenging real estate market, Five Point Holdings LLC (FPH) reported a record annual net income for 2025, driven by strategic land transactions and growth in its management business. The company also provided a bullish outlook for 2026.
The European Union has firmly rejected Iran's retaliatory designation of EU member states' armed forces as 'terrorist groups,' a move that came days after the bloc formally listed Iran's Islamic Revolutionary Guard Corps (IRGC) as a terrorist organization, escalating a diplomatic tit-for-tat.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Under Armour faces a pivotal moment as a significant insider purchase coincides with a high-stakes legal loss and the exit of its Chief Product Officer, testing investor confidence in the embattled sportswear brand's turnaround strategy.
A deep dive into Guardian Pharmacy Services (NYSE:GRDN) using a discounted cash flow model suggests its current share price is hovering close to its estimated intrinsic value. While the analysis provides a quantitative benchmark, investors are cautioned that valuation is just one piece of the puzzle in a complex and regulated healthcare sector.
Merck & Co. shares have delivered impressive multi-year returns, climbing over 80% in the past five years. Yet, a deep dive into its valuation metrics suggests the market may still be underestimating the pharmaceutical leader's intrinsic value, presenting a potential opportunity for investors.
Ondas Holdings Inc. (NASDAQ: ONDS), through its subsidiary American Robotics, has achieved a significant milestone with its Optimus drone system being added to the Defense Contract Management Agency's (DCMA) Blue List. This designation streamlines procurement for U.S. defense and critical infrastructure missions, bolstering the company's position in the competitive autonomous systems market.
